SCHEMBL3907606

SCHEMBL3907606

CC(=O)N1CCNC(=O)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
TSHR P16473 1/20 0.51
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HSP90AA1 P07900 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GFER P55789 1/20 0.44
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 2/20 0.42
TOP2A P11388 1/20 0.42
TOP2B Q02880 1/20 0.42
KDM4E B2RXH2 1/20 0.42
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PARP1 P09874 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
TGM2 P21980 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18216643 0.85 KMT2A (0.42) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL16751026 0.82 KMT2A (0.42) KMT2ATSHRPOLBTDP1GFER
SCHEMBL163317 0.81 KMT2A (0.58) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL5005151 0.79 KMT2A (0.56) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL28838729 0.79 KMT2A (0.56) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL14001959 0.79 KMT2A (0.56) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL12208862 0.79 KMT2A (0.51) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL1911510 0.79 KMT2A (0.51) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL9279600 0.79 POLB (0.52) KMT2ATSHRPOLBTDP1HSP90AA1
SCHEMBL12233461 0.79 TSHR (0.63) KMT2ATSHRPOLBTDP1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US claimed
CN-122059926-A Heterocyclic degradation determinants for target protein degradation C4医药公司 2026-05-19 CN disclosed
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
EP-4717317-A2 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2026-04-01 EP disclosed
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-3641762-B1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
EP-0107423-B1 NOVEL CHROMANS AND CHROMENES BEECHAM GROUP PLC (GB) 1986-07-23 EP disclosed
US-4496565-A HYPOTENSIVE AGENTS BEECHAM GROUP P.L.C. (GB) 1985-01-29 US disclosed
EP-0107423-A1 Novel chromans and chromenes BEECHAM GROUP PLC (GB) 1984-05-02 EP disclosed
US-4410522-A BACTERICIDES TOYAMA CHEMICAL CO., LTD. (JP) 1983-10-18 US disclosed
US-4379152-A Cephalosporins TOYAMA CHEMICAL CO., LTD. (JP) 1983-04-05 US disclosed
US-4327097-A BACTERICIDES FOR MAMMALS TOYAMA CHEMICAL CO., LTD. (JP) 1982-04-27 US disclosed
US-4219554-A Novel penicillins and cephalosporins and process for producing same TOYAMA CHEMICAL COMPANY, LIMITED (JP) 1980-08-26 US disclosed
US-4112090-A BACTERICIDE TOYAMA CHEMICAL CO., LTD. (JP) 1978-09-05 US disclosed
US-4110327-A BACTERICIDES TOYAMA CHEMICAL CO., LTD. (JP) 1978-08-29 US disclosed
US-4087424-A Novel penicillins and cephalosporins and process for producing the same TOYAMA CHEMICAL CO., LTD. (JA) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 KMT2A 1207/4885TSHR 4495/4885POLB 4265/4885
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C KMT2A 2907/4885TSHR 174/4885POLB 4356/4885
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 KMT2A 2453/4885TSHR 588/4885POLB 4498/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 KMT2A 3663/4885TSHR 380/4885POLB 2978/4885
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBLC, CBL KMT2A 2401/4885TSHR 192/4885POLB 4332/4885
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR KMT2A 288/4885TSHR 71/4885POLB 4766/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 KMT2A 1207/4885TSHR 4495/4885POLB 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.